Michael Gelband’s CorMedix CRMD Stock Holding History

Michael Gelband’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Buy	+135,804	New	+$1.07M	0.01%	1053
2025 Q3	–	Sell	-62,549	Closed	-$771K	–	1616
2025 Q2	$771K	Sell	62,549 -168,918	-73%	-$1.86M	0.01%	1037
2025 Q1	$1.43M	Buy	231,467 +152,178	+192%	+$1.58M	0.01%	821
2024 Q4	$642K	Buy	79,289 +30,424	+62%	+$304K	﹤0.01%	1079
2024 Q3	$395K	Buy	+48,865	New	+$264K	﹤0.01%	1277
2022 Q4	–	Sell	-15,298	Closed	-$43K	–	1714
2022 Q3	$43K	Buy	+15,298	New	+$63.6K	﹤0.01%	1795
2021 Q3	–	Sell	-21,310	Closed	-$146K	–	2191
2021 Q2	$146K	Buy	+21,310	New	+$170K	﹤0.01%	2064
2021 Q1	–	Sell	-26,229	Closed	-$195K	–	2177
2020 Q4	$195K	Buy	+26,229	New	+$178K	﹤0.01%	1738
2020 Q1	–	Sell	-23,003	Closed	-$167K	–	1159
2019 Q4	$167K	Buy	+23,003	New	+$141K	﹤0.01%	1370
2019 Q2	–	Sell	-37,255	Closed	-$352K	–	1134
2019 Q1	$352K	Buy	37,255 +22,815	+158%	+$206K	0.03%	423
2018 Q4	$93K	Buy	+14,440	New	+$96.6K	0.01%	315

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Michael Gelband's CRMD Position: Q2 2026 in Review

Michael Gelband opened a new position in CorMedix (CRMD) in Q2 2026: 135,804 shares worth $1.07M. The stake represents 0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: Michael Gelband previously reported a position in CRMD as recently as Q2 2025.

Michael Gelband first reported a position in CRMD in Q4 2018 and has held it in 11 quarters since. The position peaked at $1.43M in Q1 2025. 192 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Michael Gelband held 135,804 shares of CorMedix worth $1.07M as of Q2 2026.
CorMedix was a new Michael Gelband position in Q2 2026.
CorMedix made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1053 holding.
Michael Gelband first reported a position in CorMedix in Q4 2018 and has held it in 11 quarters since.
Michael Gelband's CorMedix position peaked at $1.43M in Q1 2025.
192 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.